BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Predictive Biosciences' CertNDx™ Case Study Published in BMC Urology


10/17/2012 9:36:24 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Predictive Biosciences, an innovative developer of molecular diagnostic tests, announced today that a case study using the CertNDx™ Bladder Cancer Assay was published in BMC Urology by Dr. Daniel M. Silverberg of Urology Specialists of the Lehigh Valley in Allentown, PA. The article entitled “Urothelial carcinoma of the upper urinary tract diagnosed via FGFR3 mutation detection in urine: a case report” can be accessed online at BMC Urology. FGFR3 mutations have been shown to exist in up to 50% of cancers found in the urinary bladder and upper urinary tract, but only a handful of research institutions throughout the world have attempted to detect them. With the introduction of the CertNDx Bladder Cancer Assay, a non-invasive molecular diagnostic test, urologists across the United States now have the ability to detect bladder and upper urinary tract cancers using FGFR3 mutation detection in urine. This case demonstrates the CertNDx Bladder Cancer Assay’s ability to detect an upper tract cancer in a real-world medical practice.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->